On June 12, 2020, Qin Haiqiang, deputy director of Neurology center of Beijing Tiantan Hospital, Jiang Nan, deputy director of surgery of the First Affiliated Hospital of Tsinghua University, and Lin Feng, deputy director of Neurology Department of Sanming first Central Hospital of Fujian Province, communicated with Dr. Chen Xianyang, CTO of Baofeng biology, on the clinical application of neuraminic acid, metabolic + AI analysis software platform, and the development of 5g + medical infrastructure Flow and discussion.
Ms. Chang Tingting, CEO of Baofeng Biology (first from left), Dr. Chen Xianyang (first from right), Qin Haiqiang, deputy director of Neurology center of Beijing Tiantan Hospital (Center), Jiang Nan, deputy director of Beijing Huaxin hospital (First Affiliated Hospital of Tsinghua University) (second from right), Lin Feng, deputy director of Neurology Department of Sanming first central hospital (second from left)
First of all, Dr. Chen introduced in detail the development history of Baofeng Biotechnology (Beijing) Co., Ltd., as well as the honors and related achievements obtained by the company. Studies at home and abroad have shown that neuritic acid is the core natural component of brain nerve cells and nerve tissues, and it is a specific material found in the world to promote the repair and regeneration of damaged nerve fiber tissue. Nerve acid can induce nerve fiber self growth and division, repair blocked, twisted, condensed and broken nerve fiber. As the source of myelin sheath of nervous system, neuritic acid is an important component of white matter of brain. It is used to form myelin sheath membrane and is an important raw material of myelin sheath. Problems caused by white matter lesions: cognitive decline, stroke, dementia, motor nerve disorders, cerebral atrophy, cerebrovascular disease, stroke, sensory disorders, mental diseases, sleep disorders, etc. With the development of society, the number of people over 60 years old in China has reached 249 million. The prevalence of leukoencephalopathy (including Alzheimer's disease, brain atrophy and other diseases) in the elderly in China is as high as 49.7%. The prevalence rate of the patients over 80 years old was almost 100%. Therefore, early screening, early intervention, become a just need.
With the development of precision medicine, more and more people pay attention to personalized treatment. Precision therapy driven by big data is the foundation of future medicine. In particular, medical data processing is the core technology of precision medicine and intelligent diagnosis in the future, and it is also the cornerstone of medical level progress in China. However, with the continuous development of medicine, statistics, biology and computer technology, the interdisciplinary is becoming more and more complex, and the difficulty and challenge of dealing with it are more and more big. In particular, big data research based on new research means needs not only the knowledge of traditional statistics, but also multivariate statistics, as well as new statistical analysis techniques including machine learning.
Metabonomics, as the latest system biology screening tool, can effectively improve the sensitivity of screening; while AI algorithm can find the best marker from tens of thousands of indicators of omics, and conduct overall evaluation combined with clinical information. Our metabonomics + AI technology platform can be used to evaluate the effectiveness of drugs in nervous system through the study, understanding and model construction of the whole process of patients' clinical cases, medication history, genetic background, metabolite changes and drug metabolism pathway.
Finally, Dr. Chen introduced some of the projects currently in progress, so that all parties have a preliminary understanding of the overall planning. All parties indicated that in the future cooperation, starting from the mechanism of the action of neuraminic acid and using metabolism + AI as the technical means, a series of early screening and target drug development of nervous system diseases, pharmacodynamics research, new marker screening, five Prescription Optimization, intelligent diagnosis and auxiliary diagnosis, disease prevention and epidemiology research can be carried out. This seminar will lay an important foundation for the in-depth cooperation of all parties in the future, as well as the promotion and application of neuraminic acid.
Baofeng Biotechnology (Beijing) Co., Ltd. is a national high-tech and Zhongguancun high-tech enterprise focusing on screening and intervention of nervous system diseases. The company uses cutting-edge biotechnology means (genomics, metabonomics, microbiological analysis), big data (data mining and machine learning) and AI (Artificial Intelligence) technology to develop and produce screening and intervention products with neuraminic acid as the core to provide global customers with brain health solutions.
Baofeng Biotechnology (Beijing) Co., Ltd. is a biotechnology company specializing in the research and development, production, sales and technical services of plant derived neuraminic acid and related brain health products. Nervonic acid is an important combination of nerve cell membrane recognized by scientists all over the world. It is the main structure on the branch chain of compound lipids (ganglioside, cerebroside, sphingomyelin, etc.), which provides important raw materials for normal nerve cell metabolism and repair. It is also an essential nutrient for the growth, redevelopment and maintenance of nerve cells, especially brain cells, optic nerve cells and peripheral nerves. Its lack will cause stroke sequelae, senile dementia, cerebral palsy, brain atrophy, memory loss, insomnia and amnesia. As a necessary nutrient for the brain, the in vitro uptake of neuritic acid is particularly important as the essential nutrients for the brain.